ProteomEdge
Stockholm, SE · 1 known investors
Find your way into ProteomEdge
159 people in our graph share verified history with the ProteomEdge team — schools, employers, funds. One of them is your warm intro.
Gustav von Sydowunlockedknows Henrik Everberg · together at Lund University (overlapped)
×10knows the team · via Lund University
knows the team · via Pixelgen
ProteomEdge develops mass spectrometry-based analytical platforms and proprietary heavy-labelled protein standard panels for absolute protein quantification in blood plasma, targeting clinically relevant biomarkers such as apolipoproteins, complement factors, and liver disease markers. Its products serve research and translational proteomics customers, including academic core facilities and precision medicine researchers. Based in Stockholm, Sweden.
Founders & leadership
MU
Mathias UhlénCo-founder & Chairman of the Board
HE
Henrik EverberginCEOHenrik Everberg has held R&D, operations, manufacturing, and quality leadership roles across life science companies including Phadia, Atlas Antibodies, APL, and Pixelgen Technologies, and now serves as CEO of ProteomEdge, which develops mass spectrometry platforms for protein quantification in blood plasma.
MH
Marianne HanssonFormer part-time CEO
Investors · 1
In the news
Frequently asked questions
- What does ProteomEdge do?
- ProteomEdge develops mass spectrometry-based analytical platforms and proprietary heavy-labelled protein standard panels for absolute protein quantification in blood plasma, targeting clinically relevant biomarkers such as apolipoproteins, complement factors, and liver disease markers. Its products serve research and translational proteomics customers, including academic core facilities and precision medicine researchers. Based in Stockholm, Sweden.
- Who founded ProteomEdge?
- ProteomEdge was founded by Mathias Uhlén.
- Who are ProteomEdge's investors?
- ProteomEdge's investors include Navigare Ventures.
- Where is ProteomEdge headquartered?
- ProteomEdge is headquartered in Stockholm, SE.